ProfileGDS5678 / 1438870_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 56% 57% 63% 55% 71% 56% 55% 59% 57% 57% 56% 59% 56% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4701556
GSM967853U87-EV human glioblastoma xenograft - Control 23.4378457
GSM967854U87-EV human glioblastoma xenograft - Control 33.7375663
GSM967855U87-EV human glioblastoma xenograft - Control 43.3038355
GSM967856U87-EV human glioblastoma xenograft - Control 54.4430471
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4993356
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4623655
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5573459
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4538657
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4218257
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4193356
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5107659
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4230856
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5334959